Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTissue Regenix Group Regulatory News (TRX)

  • This share is currently suspended. It was suspended at a price of 7.23
  • There is currently no data for TRX

Acquisition

13 Jun 2005 07:00

Torex Retail PLC13 June 2005 13 June 2005 TOREX RETAIL PLC CONTINUED EXPANSION OF EUROPEAN BUSINESS WITH €4.25 MILLION ACQUISITION OF LEADING GERMAN RETAIL WORKFORCE MANAGEMENT SYSTEMS SUPPLIER Torex Retail Plc ("Torex Retail" or "the Group"), the leading internationalsystems supplier, is pleased to announce that it has acquired HoffmannDatentechnik GmbH ("Hoffmann" or "the Company") for a total consideration of€4.25 million. This consideration will be satisfied by the payment of €2.50million in cash and €1.75 million by the issue of 1,146,465 new Torex Retailordinary shares payable on completion. Hoffmann is the leading supplier of workforce management and labour schedulingsystems to the German retail market. The Company has a base of over 2,500installed systems in some 300 customers in Germany, Switzerland, Austria,Belgium, Poland, Romania and the Czech Republic. The strong customer basecomprises some of Germany's largest retailers including Praktiker (Metro),Globus (Rewe), IKEA, Toys'R'Us, Douglas and EDKA. Hoffmann is based in near Bremen and in the year ended 31 December 2004 theCompany achieved revenues of €2.5 million. Chris Moore, Chief Executive of Torex Retail commented: "Hoffmann is a longstanding and well respected supplier to the European retailmarket. For a small business it has a fantastic blue chip customer base whichbears testimony to the strength of its product set and reputation for customerservice. We are already the market leader in the UK in labour scheduling with customerslike Tesco taking our solution and Hoffmann greatly increases our capabilityacross Europe. The acquisition will give rise to significant cross sellingopportunities in the German market and also provides a product which can be soldthroughout our business, including to the large US market." Application will be made for the 1,146,465 new shares to be issued pursuant tothe consideration for the acquisition to be admitted to trading on AIM.Admission is expected to become effective on 16 June 2005. Ends. Enquiries: Torex Retail plc 0870 050 9900Chris Moore, Chief ExecutiveRichard Thompson, Finance Director Citigate Dewe Rogerson 020 7638 9571Ginny Pulbrook / Seb Hoyle About Torex Retail plc Torex Retail is a leading independent provider of cutting edge retail technologysolutions to many of the world's principal retailers. Since the company'sflotation in spring 2004 Torex Retail has achieved rapid growth across all ofits markets and has rigorously pursued its goal of becoming the provider ofchoice. As a result, the company now has a presence in all of the major marketsaround the world and has built a strong platform for future growth in line withits strategy. Torex's Retail's product and solution set spans high street andout-of-town retail as well as the petroleum and convenience sector and with over2,000 blue-chip customer relationships, including Tesco, Woolworth, Selfridges,Shell and Argos, the company has earned a leading reputation amongst retailers.Torex Retail has more than 1,000 staff based across the UK, Europe, South-EastAsia and the United States. www.torexretail.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
22nd Nov 20227:00 amRNSDistribution agreement - OrthoPure® XT in Germany
14th Nov 20226:05 pmRNSHolding(s) in Company
7th Nov 20222:35 pmRNSHolding(s) in Company
29th Sep 202210:13 amRNSDirector/PDMR Shareholding
27th Sep 20227:15 amEQSHardman & Co Research on Tissue Regenix (TRX): Operating leverage
7th Sep 20227:00 amRNSHalf-year Report
22nd Aug 20223:31 pmRNSHolding(s) in Company
18th Aug 20225:36 pmRNSHolding(s) in Company
18th Aug 20222:10 pmRNSHolding(s) in Company
11th Aug 20224:30 pmEQSHardman & Co Research: Q&A on Tissue Regenix Group plc: Significantly undervalued which should correct
11th Aug 202212:46 pmRNSHolding(s) in Company
11th Aug 202212:17 pmRNSHolding(s) in Company
11th Aug 20227:00 amRNSConfirmation of Interim Results
5th Aug 20223:19 pmRNSHolding(s) in Company
1st Aug 20223:14 pmRNSHolding(s) in Company
19th Jul 20222:30 pmEQSHardman & Co Research : Tissue Regenix (TRX): Strong 1H’22 sales suggest upside potential
19th Jul 20227:00 amRNSHalf Year Trading Update and Notice of Results
18th Jul 20222:42 pmRNSHolding(s) in Company
18th Jul 20221:33 pmRNSHolding(s) in Company
15th Jul 20225:29 pmRNSHolding(s) in Company
27th Jun 20226:04 pmRNSHolding(s) in Company
27th Jun 202212:58 pmRNSHolding(s) in Company
16th Jun 20221:27 pmRNSExercise of Options and Total Voting Rights
28th Apr 20227:00 amRNSOrthoPure®XT clinical results presentation
26th Apr 20224:19 pmRNSResult of AGM
20th Apr 20224:26 pmRNSDirector/PDMR Shareholding
19th Apr 20227:15 amEQSHardman & Co Research: Tissue Regenix (TRX) On pathway to sustainability
8th Apr 20227:00 amRNSGrant of share options
6th Apr 20222:59 pmRNSDirector/PDMR Shareholding
15th Mar 20227:00 amRNSFinal year results for the year ended 31 Dec 2021
9th Mar 20227:00 amRNSDistribution agreement for OrthoPure® XT
2nd Mar 20227:00 amRNSNotice of Results
10th Feb 20223:45 pmRNSAdditional Director Disclosures
27th Jan 20227:00 amRNSFull Year Trading update
23rd Dec 20217:00 amRNSDirector/PDMR Shareholding
21st Dec 20212:06 pmRNSSecond Price Monitoring Extn
21st Dec 20212:01 pmRNSPrice Monitoring Extension
19th Oct 20211:15 pmEQSHardman & Co Research: Tissue Regenix (TRX): Faster-than-anticipated recovery
8th Oct 20217:00 amRNSHolding(s) in Company
5th Oct 20214:44 pmRNSHolding(s) in Company
28th Sep 20217:00 amRNSHolding(s) in Company
24th Sep 20212:05 pmRNSDirector/PDMR Shareholding
9th Sep 20214:35 pmRNSDirector/PDMR Shareholding
8th Sep 20217:00 amRNSHalf-year Report
1st Sep 20217:00 amRNSLaunch of DermaPure® Meshed and VNEWTM
1st Sep 20217:00 amRNSNotice of Results
16th Aug 20217:00 amRNSHolding(s) in Company
14th Jul 20213:15 pmEQSHardman & Co Research: Q&A with Dr Martin Hall on Tissue Regenix Group Plc: New capacity now on stream
30th Jun 202111:56 amEQSHardman & Co Research: Tissue Regenix (TRX): Poised for growth
29th Jun 20211:00 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.